Advertisement

European Journal of Epidemiology

, Volume 28, Issue 6, pp 493–502 | Cite as

20-Year prevalence projections for dementia and impact of preventive policy about risk factors

  • Hélène Jacqmin-GaddaEmail author
  • Annick Alperovitch
  • Claire Montlahuc
  • Daniel Commenges
  • Karen Leffondre
  • Carole Dufouil
  • Alexis Elbaz
  • Christophe Tzourio
  • Joël Ménard
  • Jean-François Dartigues
  • Pierre Joly
NEUROEPIDEMIOLOGY

Abstract

Incidence of dementia increases sharply with age and, because of the increase in life expectancy, the number of dementia cases is expected to rise dramatically over time. Some studies suggest that controlling some modifiable risk factors for dementia like diabetes or hypertension could lower its incidence. However, as treating these vascular factors would also reduce mortality risk, the actual impact of such public-health intervention on dementia prevalence is not known. Accounting for the impact of dementia and risk factors on mortality, the aim of this work was (1) to compute projections of age- and-sex specific prevalence of dementia in France from 2010 to 2030, (2) to evaluate how public-health interventions targeting risk factors for dementia could change these projections. Age-and-sex specific incidence of dementia and mortality of demented subjects were estimated from the Paquid population-based cohort using a semi-parametric illness-death model. Future global mortality rates and population sizes were obtained from national demographic projections. Under the assumption that life expectancy will increase by 3.5 years for men and 2.8 years for women by 2030, the number of subjects with dementia was estimated to increase by about 75 % from 2010 to 2030 with a 200 % increase after 90 years of age. Therapeutic intervention on the whole population reducing high blood pressure prevalence would lead to a decrease in both dementia incidence rates and mortality and would have a modest impact on the number of dementia cases. On the other hand, a preventive dementia treatment targeting ApoE4 carriers would probably not improve survival and hence would decrease dementia prevalence by 15–25 %.

Keywords

Dementia Incidence Mortality Prevalence Projection 

Notes

Acknowledgments

PAQUID is partly funded by IPSEN and Novartis Laboratories.

References

  1. 1.
    Gallez C. Rapport sur la maladie d alzheimer et les maladies apparentées. Office Parlementaire d’Évaluation des Politiques de Santé, Bibliothèque des Rapports Publics. http://www.assembleenationale.fr/12/rap-off/i2454.asp (2005).
  2. 2.
    Alzheimer-Association. Alzheimer’s disease facts and figures. Alzheimers Dement. 2012;8:131–168.CrossRefGoogle Scholar
  3. 3.
    Polidori MC, Pientka L, Mecocci P. A review of the major vascular risk factors related to alzheimer’s disease. J Alzheimers Dis. 2012;32:521–530.Google Scholar
  4. 4.
    Barnes DE, Yaffe K. The projected effect of risk factor reduction on alzheimer’s disease prevalence. Lancet Neurol. 2011;10(9):819–828.PubMedCrossRefGoogle Scholar
  5. 5.
    Brookmeyer R, Gray S, Kawas C. Projections of alzheimer’s disease in the united states and the public health impact of delaying disease onset. Am J Public Health 1998;88(9):1337–1342.PubMedCrossRefGoogle Scholar
  6. 6.
    Brookmeyer R, Gray S. Methods for projecting the incidence and prevalence of chronic diseases in ageing populations: application to alzheimer’s disease. Stat Med. 2000;19(11–12):1481–1493.PubMedCrossRefGoogle Scholar
  7. 7.
    Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of alzheimer’s disease. Alzheimers Dement. 2007;3(3):186–191.PubMedCrossRefGoogle Scholar
  8. 8.
    Mura T, Dartigues JF, Berr C. How many dementia cases in france and europe? Alternative projections and scenarios 2010–2050. Eur J Neurol. 2010;17(2):252–259.PubMedCrossRefGoogle Scholar
  9. 9.
    Joly P, Commenges D, Helmer C, Letenneur L. A penalized likelihood approach for an illness-death model with interval-censored data: application to age-specific incidence of dementia. Biostatistics 2002;3(3):433–443.PubMedCrossRefGoogle Scholar
  10. 10.
    Ostbye T, Hill G, Steenhuis R. Mortality in elderly Canadians with and without dementia: a 5-year follow-up. Neurology 1999;53(3):521–526.PubMedCrossRefGoogle Scholar
  11. 11.
    Jagger C, Andersen K, Breteler MM, Copeland JR, Helmer C, Baldereschi M, et al. Prognosis with dementia in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54(11 supp l5):S16–S20.Google Scholar
  12. 12.
    Ramaroson H, Helmer C, Barberger-Gateau P, Letenneur L, Dartigues JF. Prevalence of dementia and Alzheimer’s disease among subjects aged 75 years or over: updated results of the PAQUID cohort. Rev Neurol. 2003;159(4):405–411.PubMedGoogle Scholar
  13. 13.
    Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a delphi consensus study. Lancet 2006;366(9503):2112–2117.CrossRefGoogle Scholar
  14. 14.
    WHO. World health report 2002. Reducing risks, promoting healthy life. Geneva: WHO, 2002. World Health Organization, Geneva, Switzerland, http://www.who.int/whr/2002 (2002).
  15. 15.
    Duron E, Hanon O. Hypertension, cognitive decline and dementia. Arch Cardiovasc Dis. 2008;101(3):181–189.PubMedCrossRefGoogle Scholar
  16. 16.
    Tolppanen AM, Solomon A, Soininen H, Kivipelto M. Midlife vascular risk factors and alzheimer’s disease: evidence from epidemiological studies. J Alzheimers Dis. 2012;32:531–540.Google Scholar
  17. 17.
    Power MC, Weuve J, Gagne JJ, McQueen MB, Viswanathan A, Blacker D. The association between blood pressure and incident alzheimer disease: a systematic review and meta-analysis. Epidemiology 2011;22(5):646–659.PubMedCrossRefGoogle Scholar
  18. 18.
    Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein e genotype and alzheimer disease. JAMA 1997;278(16):1349–1356.PubMedCrossRefGoogle Scholar
  19. 19.
    Genin E, Hannequin D, Wallon D, Sleegers K, Hiltunen M, Combarros O, et al. Apoe and alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry 2011;16(9):903–907.PubMedCrossRefGoogle Scholar
  20. 20.
    Tilvis RS, Kähönen-Väre MH, Jolkkonen J, Valvanne J, Pitkala KH, Strandberg TE. Predictors of cognitive decline and mortality of aged people over a 10-year period. J Gerontol A Biol Sci Med Sci. 2004;59(3):M268–M274.CrossRefGoogle Scholar
  21. 21.
    Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, et al. Apoe-directed therapeutics rapidly clear {beta}-amyloid and reverse deficits in ad mouse models. Science 2012;335(6075):1503–1506.PubMedCrossRefGoogle Scholar
  22. 22.
    Strittmatter WJ. Old drug, new hope for alzheimers disease. Science 2012;335(6075):1447–1448.PubMedCrossRefGoogle Scholar
  23. 23.
    Joly P, Touraine C, Georget A, Dartigues JF, Commenges D, Jacqmin-Gadda H. Prevalence projections of chronic diseases and impact of public health intervention. Biometrics 2013;69:109–117.Google Scholar
  24. 24.
    Keiding N. Age-specific incidence and prevalence: a statistical perspective. J R Stat Soc Series A 1991;154(3):371–412.CrossRefGoogle Scholar
  25. 25.
    Blanpain N, Chardon O. Projections de population 2007–2060 pour la france métropolitaine: méthode et principaux résultats. Document de travail 2010;F1008. http://alexandre.cor-retraites.fr/IMG/pdf/doc-1446.pdf.
  26. 26.
    Commenges D, Joly P, Letenneur L, Dartigues JF. Incidence and mortality of Alzheimer’s disease or dementia using an illness-death model. Stat Med. 2004;23:199–210.PubMedCrossRefGoogle Scholar
  27. 27.
    Gompertz Benjamin. On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies. Philos Trans R Soc Lond. 1825;115:513–583.CrossRefGoogle Scholar
  28. 28.
    Blanpain N, Chardon O. Projections de population à l’horizon 2060. un tiers de la population âgé de plus de 60 ans. Insee première 2010;1320:1–4.Google Scholar
  29. 29.
    Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, et al. Incident dementia and blood pressure lowering in the hypertension in the very elderly trial cognitive function assessment (hyvet-cog): a double-blind, placebo controlled trial. Lancet Neurol. 2008;7(8):683–689.PubMedCrossRefGoogle Scholar
  30. 30.
    Dahlöf B, Hansson L, Lindholm LH, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the swedish trial in old patients with hypertension (stop-hypertension). Lancet 1991;338(8778):1281–1285.PubMedCrossRefGoogle Scholar
  31. 31.
    Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000;355(9207):865–872.PubMedCrossRefGoogle Scholar
  32. 32.
    Winnock M, Letenneur L, Jacqmin-Gadda H, Dallongeville J, Amouyel P, Dartigues JF. Longitudinal analysis of the effect of apolipoprotein e ε 4 and education on cognitive performance in elderly subjects: the paquid study. J Neurol Neurosurg Psychiatry 2002;72(6):794–797.PubMedCrossRefGoogle Scholar
  33. 33.
    Law MR, Morris JK, Wald NJ, et al. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338(191):1245–1253.Google Scholar
  34. 34.
    Fratiglioni L, Launer LJ, Andersen K, Breteler MM, Copeland JR, Dartigues JF, et al. Incidence of dementia and major subtypes in europe: a collaborative study of population-based cohorts. neurologic diseases in the elderly research group. Neurology 2000;54(11 Suppl 5): S10.PubMedGoogle Scholar
  35. 35.
    Schrijvers EMC, Verhaaren BFJ, Koudstaal PJ, Hofman A, Ikram MA, Breteler MMB. Is dementia incidence declining? Trends in dementia incidence since 1990 in the rotterdam study. Neurology 2012;78(19):1456–1463.PubMedCrossRefGoogle Scholar
  36. 36.
    Rocca WA, Petersen RC, Knopman DS, Hebert LE, Evans DA, Hall KS, et al. Trends in the incidence and prevalence of alzheimers disease, dementia, and cognitive impairment in the united states. Alzheimers Dement. 2011;7(1):80–93.PubMedCrossRefGoogle Scholar
  37. 37.
    Commenges D, Joly P, Gégout-Petit A, Liquet B. Choice between semi-parametric estimators of markov and non-markov multi-state models from coarsened observations. Scand J Stat. 2006;34(1):33–52.CrossRefGoogle Scholar
  38. 38.
    Amieva H, Le Goff M, Millet X, Orgogozo JM, Pérès K, Barberger-Gateau P, et al. Prodromal alzheimer’s disease: successive emergence of the clinical symptoms. Ann Neurol. 2008;64(5):492–498.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Hélène Jacqmin-Gadda
    • 1
    • 2
    • 3
    Email author
  • Annick Alperovitch
    • 4
    • 5
  • Claire Montlahuc
    • 4
    • 5
  • Daniel Commenges
    • 2
    • 3
  • Karen Leffondre
    • 2
    • 3
  • Carole Dufouil
    • 4
    • 5
  • Alexis Elbaz
    • 6
    • 7
  • Christophe Tzourio
    • 4
    • 5
  • Joël Ménard
    • 8
  • Jean-François Dartigues
    • 2
    • 3
  • Pierre Joly
    • 2
    • 3
  1. 1.Inserm U897,ISPEDUniversité Bordeaux SégalenBordeaux CedexFrance
  2. 2.Université de BordeauxISPED, Centre Inserm U897BordeauxFrance
  3. 3.Inserm, ISPED, Centre Inserm U897BordeauxFrance
  4. 4.Université de BordeauxU708BordeauxFrance
  5. 5.Inserm, U708BordeauxFrance
  6. 6.Inserm, U1018VillejuifFrance
  7. 7.Université Versailles St-QuentinUMRS 1018VillejuifFrance
  8. 8.Faculté de Médecine Paris-DescartesParisFrance

Personalised recommendations